Scholarlink

Antibody-drug conjugates (ADCs) have come to the age of fruition following a long period of trials and errors. Eleven ADCs have been approved by the Food and Drug Administration (FDA) thus far and many more are in the development pipelines. This chapter provides the current landscape of ADC drug discovery and development. It summarizes the major players in ADC drug development worldwide, recently completed or currently running late-stage clinical trials registered in the United States, recently US patents issued, and patent applications published. In addition, the cost and outcomes aspects of ADC drug therapy are discussed.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Major ADC Companies, Current Late-Stage Clinical Trials, Recent Patents Issued and Patent Applications Published, and Cost Analysis of Drug Therapy

  • 章节

  • 发表日期：

    2025年

查看全文
  • Jeffrey Wang,
  • Aryana Sepassi,
  • Jonathan H. Watanabe

摘要

Antibody-drug conjugates (ADCs) have come to the age of fruition following a long period of trials and errors. Eleven ADCs have been approved by the Food and Drug Administration (FDA) thus far and many more are in the development pipelines. This chapter provides the current landscape of ADC drug discovery and development. It summarizes the major players in ADC drug development worldwide, recently completed or currently running late-stage clinical trials registered in the United States, recently US patents issued, and patent applications published. In addition, the cost and outcomes aspects of ADC drug therapy are discussed.